MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) has significantly bolstered its executive team by welcoming four industry professionals to its ranks. The move highlights Annovis’s efforts to innovative leadership and industry expertise, which could profoundly impact the company’s future achievements.
First on the list of the new hires is Mark White, a seasoned pharmaceutical marketing expert who joins as the Chief Business Officer. His multiple stints at global giants such as Pfizer, Abbott, Bayer, and Bracco have imparted him with profound industry knowledge. Mr. White’s prior role at Pfizer saw him managing international new product development, marketing, and business development in the Inflammation Therapeutic Area.
Next, Dr. Alexander Morin brings a unique blend of science and communication skills as the newly appointed Director of Strategic Communications. With a history of enhancing corporate communication strategies for various clients, including biotech firms and non-profit organizations, Dr. Morin is poised to play a crucial role in Annovis Bio’s public relations strategy.
The third addition is Hilda Maibach who is set to serve as the Senior Vice President of Statistics. Ms. Maibach brings a wealth of experience from the industry and academic field and has dedicated her career to exponentially improving the sensitivity of clinical trials, revolutionizing the design of clinical trials, and enhancing data acquisition and management.
Lastly, the company has announced the appointment of Blake Jensen as Head of Quality. Jensen, with his two decades of quality experience in the biopharma industry and a previous role as an investigator for the U.S. FDA, could significantly enhance Annovis Bio’s quality assurance aspect.
“We are delighted to have this strong group of individuals join the Annovis team,” said Maria Maccecchini, Ph.D., Founder, President, and CEO of Annovis Bio. “Their expertise and leadership are critical in this pivotal moment in our company, as we continue making strides towards bringing buntanetap closer to NDA and to market for Alzheimer’s and Parkinson’s diseases.”
With these key appointments, Annovis Bio is setting its sights on taking significant strides in the pharmaceutical industry, particularly in developing new drugs for Alzheimer’s and Parkinson’s diseases. Maria Maccecchini, Founder, President, and CEO of Annovis Bio, expressed delight at the new additions, as their expertise and leadership are expected to play a crucial part in this pivotal moment for the company.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.